CD34 and melanoma: A clinical trial conducted by Banchereau and colleagues for similarly advanced-stage melanoma patients using bulk CD34+ HPC-derived DCs, which included LCs, pulsed with a mixture of melanoma-derived peptides, resulted in durable immune responses associated with long-term survival [25].